Page 40 - CPG endometrial cancer

แนวทางการตรวจคดั กรอง วินิจฉัยและรักษาโรคมะเรง็ เยื่อบุโพรงมดลกู 3375

เอกสารอา้ งอิง

1. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in
advanced endometrial cancer. N Engl J Med 2023;388(23):2159-2170.

2. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov?k Z, Black D, et al. Dostarlimab for primary
advanced or recurrent endometrial cancer. N Engl J Med 2023;388(23):2145-2158.

3. Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, et al. Phase 3, randomized, open- label study of
pembrolizumab plus lenvatinib versus chemotherapy for first - line treatment of advanced or recurrent
endometrial cancer: ENGOT- en/9LEAP- 001. Int J Gynecol Cancer 2022; .100–93:32doi:/1136.10ijgc-003017-2021

4. Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized Phase II Trial of Carboplatin-
paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human
epidermal growth factor receptor 2/neu. J Clin Oncol 2018;36(20):2044-2051.

5. Koppikar S, Oaknin A, Babu KG, Lorusso D, Gupta S, Wu LY, et al. Pan-Asian adapted ESMO Clinical Practice
Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer. ESMO Open
2023;8(1):100774.

6. Moore KN, Tian C, McMeekin DS, Thigpen JT, Randall ME, Gallion HH. Does the progression-free interval after primary
chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a
Gynecologic Oncology Group ancillary data analysis. Cancer 2010;116(23):5407-5414.

7. Rubinstein M, Halpenny D, Makker V, Grisham RN, Aghajanian C, Cadoo K. Retreatment with carboplatin and
paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center
experience. Gynecol Oncol Rep 2019 Apr 5;28:120-123.

8. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin
with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
J Clin Oncol 2004;22(11):2159-2166.

9. Rose PG, Ali S, Moslemi-Kebria M, Simpkins F. Paclitaxel, carboplatin, and bevacizumab in advanced and recurrent
endometrial carcinoma. Int J Gynecol Cancer 2017;27:452-458.

10. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, et al. Phase III randomized trial of doxorubicin
+cisplatin versus doxorubicin + 24-h paclitaxel +filgrastim in endometrial carcinoma: a Gynecologic Oncology Group
study. Ann Oncol 2004; 15: 1173–8.

11. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, et al. Pembrolizumab in patients
with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol
2022;40(7):752-761.

12. Oaknin A, Tinker AV, Gilbert L, Samou?lian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti-
programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-
deficient endometrial cancer: A nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6(11):1766-1772.

13. Makker V, Colombo N, Casado Herr?ez A, Monk BJ, Mackay H, Santin AD, et al. Lenvatinib Plus Pembrolizumab in
previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study
309/KEYNOTE-775. J Clin Oncol 2023;41(16):2904-2910.

14. Casey L, Singh N. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society
Session at the USCAP 2020 Annual Meeting. Int J Gynecol Pathol 2021; 40: 5-16.